Back to search

Article

Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025

2026-08-17

Abstract excerpt

<h4>Background: </h4> /Objectives. Respiratory syncytial virus (RSV) is an important cause of acute lower respiratory infection in infants. Panama introduced the bivalent prefusion F vaccine (RSVpreF) for administration between 32.0 and 36.6 weeks of gestation in July 2025. In this tropical setting, respiratory viruses are detected throughout the year, with RSV activity increasing during the rainy season. We chara...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0d3db74f-9814-5aa8-9a73-72f6aeb241d2
DOI
10.20944/preprints202608.1049.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Safety Profile of the Bivalent RSVpreF Vaccine (Abrysvo®) Administered During Pregnancy: An Active Real-World Pharmacovigilance Study in Panama, 2025DOI 10.20944/preprints202608.1049.v1
Select a neighboring publication to make it the new centre.